NAIC Consumer Reps. Carl Schmid and Deb Darcy discuss barriers consumers face in accessing healthcare through the high number of prior authorizations and the appeals and denials process, and request the NAIC develop a workstream that improves data collection, and consumer awareness of the appeals process, update model laws, and better enforcement of federal and state laws and regulations.
Tackling copay accumulator and maximizers
Carl Schmid participates in the “Prescription for Better Access” podcast with Lauren Crawford Shaver and hosts Mark Hansan and Dr. Scott Howell to examine how PBM copay accumulator and maximizer policies harm patients by not counting copay assistance toward patient out-of-pocket costs and deductibles, and what can be done to keep prescription drugs accessible and affordable.
Generating optimism about the linkage to care for viral hepatitis
Carl Schmid, executive director of the HIV+Hepatitis Policy Institute, is excited about the new Eliminate Hepatitis C (HCV) program put forth by the Biden Administration and being led by former NIH Director Francis Collins, MD, PhD, who is serving as a scientific advisor to the Biden Administration. “This is something we have been asking for years…We know we can end hepatitis C,” Schmid stated.
Federal funding needed for a national PrEP program
Carl Schmid and Kevin Herwig present HIV + Hepatitis Policy Institute’s study modeling how much funding is required for a national PrEP program to reduce disparities, cover medications and ancillary services such as clinic visits and laboratory testing for the uninsured, and to increase outreach and adherence services.
Barriers to health care for consumers with insurance: Prior authorization
NAIC Consumer Representative Carl Schmid speaks at the 2023 NAIC Spring Meeting on a panel about how insurers create barriers to prescription drugs through onerous prior-authorization requirements.